Sample Page
Author:
Rezolute, Inc.
Posted Date:
May 1, 2026
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Rezolute, Inc.
May 1, 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Rezolute, Inc.
April 21, 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Rezolute, Inc.
March 24, 2026
Rezolute to Participate in the Citizens Life Sciences Conference
Rezolute, Inc.
March 4, 2026
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute, Inc.
February 12, 2026
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rezolute, Inc.
February 4, 2026
